Botulinum toxin type A (BOTOX) for treatment of migraine

An open-label study and 2 double-blind, placebo-controlled studies have pro vided supporting evidence of botulinum toxin type A (BTX-A) as an effective , well-tolerated treatment for migraine. Observed durations of benefit were consistent with known properties of BTX-A, Findings suggest that response may vary by features of preinjection headaches, such as migraine frequency. The precise mechanism by which BTX-A provides pain relief is hypothesized to be related not only to acetylcholine inhibition but also to a blocking a ction on the parasympathetic nervous system. Additional studies that contro l factors likely to be related to response may lead to better understanding of the BTX-A effect on migraine and an optimal treatment protocol. Copyrig ht (C) 2001 by W,B. Saunders Company.